Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
95% Confidence Interval
9%
Acrolein
12%
Aldehyde Dehydrogenase 2 (ALDH2)
9%
Arteriovenous Fistula
28%
Arteriovenous Fistula Patency
10%
Arteriovenous Graft
13%
Asymmetric Dimethylarginine
12%
Atrial Fibrillation
7%
Chronic Kidney Disease
31%
Clinical Outcomes
10%
Continuous Erythropoietin Receptor Activator
11%
COVID-19
7%
Diabetic Kidney Disease
12%
Dialysis
15%
Dialysis Membrane
10%
Dialysis Patients
8%
End-stage Renal Disease
11%
Erythropoiesis-stimulating Agents
10%
Far-infrared
7%
Far-infrared Therapy
35%
Genotype
7%
Hazard Ratio
15%
Hematocrit
9%
Heme oxygenase-1 (HO-1)
13%
Hemodialysis
46%
Hemodialysis Patients
78%
Hemodialysis Vascular Access
12%
High Risk
7%
Hypertension
7%
Hypoglycemia
7%
Kidney Disease
9%
Kidney Fibrosis
10%
Kidney Function
9%
Maintenance Hemodialysis Patients
22%
Mitochondrial Dysfunction
7%
National Cohort Study
12%
Patency
20%
Perfluorohexane Sulfonate (PFHxS)
7%
Peritoneal Dialysis
41%
Peritoneal Dialysis Catheter Insertion
10%
Peritoneal Dialysis Patients
28%
Proteinuria
10%
Randomized Controlled Trial
12%
Retrospective Cohort Study
9%
Risk Factors
13%
Taiwan
25%
Uremic Patients
14%
Vascular Access
27%
Vascular Thrombosis
7%
Yoga
8%
Medicine and Dentistry
ACE Inhibitor
7%
Angiotensin Receptor Antagonist
6%
Ankle Brachial Index
6%
Apoplexy
7%
Arteriovenous Fistula
32%
Blood Pressure
8%
Cardiovascular Disease
6%
Cardiovascular System
8%
Chronic Kidney Disease
32%
Cohort Analysis
7%
Cohort Effect
7%
Creatinine
9%
Diabetes Mellitus
10%
Dialysis Catheter
10%
End Stage Renal Disease
22%
Glomerulonephritis
7%
Hazard Ratio
10%
Health Care Cost
5%
Heat Therapy
31%
Heme Oxygenase 1
5%
Hemodialysis
100%
Hypoglycemia
6%
Immunosuppressant
6%
Infection
5%
Kidney Function
7%
N(g),n(g) Dimethylarginine
9%
Nephrology
9%
Nephropathy
7%
Nodular Goiter
6%
Peritoneal Dialysis
57%
Pneumocystis Pneumonia
6%
Polycystic Kidney Disease
6%
Prevalence
12%
Prognostic Factor
7%
Proportional Hazards Model
5%
Proteinuria
9%
Quality of Life
5%
Randomized Controlled Trial
9%
Renal Replacement Therapy
7%
Renin Angiotensin Aldosterone System
5%
Retrospective Cohort Study
8%
Therapeutic Modality
5%
Thrombosis
9%
Thyroid Disease
6%
Urinary System
7%
Vascular Access
40%
Yoga
9%
Pharmacology, Toxicology and Pharmaceutical Science
6 N,n' Dimethylarginine
6%
Acrolein
15%
Acute Kidney Failure
7%
Aldehyde Dehydrogenase Isoenzyme 2
9%
Angiotensin
5%
Angiotensin Receptor Antagonist
6%
Arteriovenous Fistula
22%
Atrial Fibrillation
8%
C Reactive Protein
8%
Cardiovascular Disease
7%
Cerebrovascular Accident
7%
Chronic Kidney Failure
16%
Cohort Study
18%
Congestive Heart Failure
12%
Continuous Erythropoiesis Receptor Activator
11%
Coronary Artery Disease
8%
Coronavirinae
12%
Creatinine
8%
Diabetes Mellitus
8%
Diabetic Nephropathy
11%
Dipeptidyl Carboxypeptidase Inhibitor
7%
Dipeptidyl Peptidase IV Inhibitor
6%
Diseases
10%
End Stage Renal Disease
13%
Glucose
5%
Heart Failure with Reduced Ejection Fraction
5%
Heme Oxygenase 1
6%
Hemodialysis
80%
Hypertension
8%
Infection
7%
Inflammation
16%
Kidney Disease
5%
Lipid
6%
N(g),n(g) Dimethylarginine
6%
Pathophysiology
6%
Perfluorooctanesulfonic Acid
8%
Randomized Controlled Trial
6%
Renin
5%
Valsartan/Sacubitril
6%